The Antiviral Factor SERINC5 Impairs the Expression of Non-Self-DNA

Viruses. 2023 Sep 20;15(9):1961. doi: 10.3390/v15091961.

Abstract

SERINC5 is a restriction factor that becomes incorporated into nascent retroviral particles, impairing their ability to infect target cells. In turn, retroviruses have evolved countermeasures against SERINC5. For instance, the primate lentiviruses (HIV and SIV) use Nef, Moloney Murine Leukemia Virus (MLV) uses GlycoGag, and Equine Infectious Anemia Virus (EIAV) uses S2 to remove SERINC5 from the plasma membrane, preventing its incorporation into progeny virions. Recent studies have shown that SERINC5 also restricts other viruses, such as Hepatitis B Virus (HBV) and Classical Swine Fever Virus (CSFV), although through a different mechanism, suggesting that SERINC5 can interfere with multiple stages of the virus life cycle. To investigate whether SERINC5 can also impact other steps of the replication cycle of HIV, the effects of SERINC5 on viral transcripts, proteins, and virus progeny size were studied. Here, we report that SERINC5 causes significant defects in HIV gene expression, which impacts virion production. While the underlying mechanism is still unknown, we found that the restriction occurs at the transcriptional level and similarly affects plasmid and non-integrated proviral DNA (ectopic or non-self-DNA). However, SERINC5 causes no defects in the expression of viral RNA, host genes, or proviral DNA that is integrated in the cellular genome. Hence, our findings reveal that SERINC5's actions in host defense extend beyond blocking virus entry.

Keywords: HIV; SERINC5; ectopic DNA; non-self-DNA; transcriptional restriction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents
  • Cell Membrane
  • Classical Swine Fever Virus*
  • DNA
  • HIV Infections*
  • Horses
  • Mice
  • Proviruses
  • Retroviridae
  • Swine

Substances

  • Antiviral Agents
  • DNA

Grants and funding

This research received no external funding. This work was supported by a pilot award from the Department of Microbiology and Immunology at the University of Rochester Medical Center (OP212337).